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Abstract 
Pyruvate carboxylase (PC) catalyzes the conversion of pyruvate to oxaloacetate (OAA), an 
important metabolic reaction in a wide range of organisms. Small molecules directed against 
PC would enable detailed studies on the metabolic role of this enzyme and would have the 
potential to be developed into pharmacological agents. Currently, specific and potent small 
molecule regulators of PC are unavailable. To assist in efforts to find, develop, and 
characterize small molecule effectors of PC, a novel fixed-time assay has been developed 
based on the reaction of OAA with the diazonium salt, Fast Violet B (FVB), which produces a 
colored adduct with an absorbance maximum at 530 nm. This fixed time assay is reproducible, 
sensitive and responsive to known effectors of Rhizobium etli PC, Staphylococcus aureus PC, 
and Listeria monocytogenes PC, and is highly amenable to high-throughput screening. The 
assay was validated using a plate uniformity assessment test and a pilot screen of a library of 
1280 compounds. The results indicate that the assay is suitable for screening small molecule 
libraries to find novel small molecule effectors of PC. 
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Introduction 
Pyruvate carboxylase (PC) is a biotin-dependent metabolic enzyme that catalyzes the 
conversion of pyruvate to oxaloacetate (OAA) through a MgATP-dependent carboxyl group 
transfer from HCO3− to pyruvate. The reaction occurs in two distinct active sites located in the 
biotin carboxylase (BC) and the carboxyltransferase (CT) domains of the enzyme [1]. A 
tethered biotin cofactor is initially carboxylated by HCO3− in the BC domain, with the 
concomitant cleavage of MgATP. The carboxybiotin cofactor is subsequently transferred to the 
CT domain, which facilitates the carboxyl group transfer from carboxybiotin to pyruvate, 
forming OAA [1]. This anaplerotic reaction serves to replenish tricarboxylic acid cycle (TCA) 
intermediates that are lost to alternative biosynthetic reactions [2]. Recent studies have linked 
aberrant PC activity to several diseases and infections, such as type 2 diabetes, listeriosis, and 
certain types of cancers [[3], [4], [5], [6], [7], [8], [9], [10]]. Many of these studies have revealed a 
correlation between reduced PC expression/activity and decreased insulin release, while 
enhanced PC expression and activity has been associated with tumor cell proliferation and 
breast cancer metastases [3,4,7,11]. Additionally, PC is necessary for the pathogenicity of Listeria 
monocytogenes, a facultative intracellular bacterium [8,12,13]. 
While there is a growing realization that PC activity is implicated in a wide range of diseases 
and infections, at present, there are no specific and potent small molecule effectors available 
to study altered PC activity in vitro or in vivo. A number of small molecules are known to alter 
PC activity [14,15], but none of these demonstrate high binding affinities and many of them are 
promiscuous. Oxalate for example, is an inhibitor of PC with a Ki value of 12 μM (chicken liver 
PC [14]), but is also a known metal chelator [16] that inhibits lactate dehydrogenase (LDH) [17] 
and transcarboxylase [18]. Specific and potent small molecule effectors have great potential to 
be used as biochemical tools to aid in delineating the structure, mechanism, and regulation of 
PC, as well as informing on its role in infection and disease. The development of a high-
throughput assay is an important prerequisite in discovering new and potent effectors of PC 
activity. 
Several well-established coupled-enzyme assays are available to study PC activity [19,20], but 
none of these are well suited to high throughput screening (HTS) of small molecule effectors. 
The PC-catalyzed carboxylation of pyruvate is typically measured by coupling the formation of 
the product, OAA, to the malate dehydrogenase (MDH) catalyzed reduction of OAA to malate 
and oxidation of NADH to NAD+ [20]. In addition, there are a variety of other coupled-enzyme 
assays that can measure the specific half-reactions catalyzed in either the BC or CT domains. 
For example, an LDH-coupled assay can be used to determine the rate of OAA 
decarboxylation in the CT domain by the NADH-dependent reduction of pyruvate to lactate. 
Similarly, a glucose-6-phospate dehydrogenase/phosphoglucomutase/phosphorylase coupled 
assay system can be used to determine the rate of MgATP cleavage in the BC domain [19]. 
These coupled-enzyme assays are generally inappropriate for screening large libraries of 
small molecules. For instance, the inclusion of secondary coupling enzymes raises the 
potential for small molecules to target the coupling enzyme instead of, or in addition to, the 
target enzyme. While counter-screens of small molecules against the coupling enzyme are 
routinely implemented in HTS programs, these represent an additional step that must be 
performed to eliminate false positives [21,22]. Furthermore, the vast majority of coupled-enzyme 
assays make use of redox enzymes that act on NAD/NADH, requiring absorbance changes to 
be monitored at 340 nm. This wavelength is suboptimal for the small assay volumes typical of 
HTS assays, where short path lengths and low extinction coefficients limit the signal window in 
a multi-well plate format [[23], [24], [25]]. Additionally, absorbance at 340 nm is subject to 
interference from small molecules, dust particles and standard assay components [23,25], 
resulting in an increased signal to noise ratio and an increased number of false positives. 
To overcome the limitations associated with using coupled-enzyme assays, a novel 96-multi-
well plate and fixed-time assay has been developed. The assay is based on the reaction of 
OAA, the product of the PC-catalyzed reaction, with Fast Violet B (FVB), a diazonium salt 
which produces a colored adduct with an absorbance maximum at 530 nm (Fig. 1). Diazonium 
salts have previously been used to detect OAA formation in other enzymatic systems such as 
phosphoenolpyruvate carboxylase and aspartate transaminase [[26], [27], [28], [29], [30]], but FVB has 
never been applied to determine PC activity. The assay readout is stable for an extended time 
period and accurately reports on enzyme activity from a single data point. The FVB fixed-time 
assay is reproducible, sensitive and responsive to known effectors of PC. The assay was used 
to screen a series of small molecule libraries that establishes it as an excellent primary assay 
for a concerted HTS program directed against PC. 
 
Fig. 1. Proposed mechanism for the reaction of oxaloacetate with Fast Violet B. 
Materials and methods 
Pyruvate carboxylase protein expression and purification 
Rhizobium etli PC (RePC) was co-expressed from a modified pET-17b-(His)9 vector [31] with a 
pCY216 vector [32] encoding E. coli biotin protein ligase (BirA) in E. coli BL21Star(DE3) cells. 
Staphylococcus aureus PC (SaPC) [33] and Listeria monocytogenes PC (LmPC) were co-
expressed from a pET-28a vector with a pCY216 vector in E. coli BL21Star(DE3) cells. RePC, 
LmPC and SaPC were purified using Ni2+-affinity and anion exchange chromatography as 
previously described [34]. In all cases, harvested cells were re-suspended in a lysis buffer 
containing 20 mM Tris (pH 7.8), 5 mM imidazole, 200 mM NaCl, 0.5 mM EGTA, 6 mM 2-
mercaptoethanol, 300 μg/mL lysozyme, 1 mM phenylmethane-sulfonyl fluoride (PMSF), 1 μM 
pepstatin A, and 5 μM proteinase inhibior E−64. Cells were disrupted by sonication and the cell 
lysate was cleared by centrifugation at 4 °C prior to loading onto a 10 mL Ni2+-NTA Profinity 
resin column (Bio-Rad Laboratories). The column was washed with 150 mL of lysis buffer 
followed by 150 mL of wash buffer (20 mM Tris; pH 7.8, 20 mM imidazole, 200 mM NaCl, 
0.5 mM EGTA, 6 mM 2-mercaptoethanol). The RePC enzyme was eluted from the column in 
elution buffer (20 mM Tris; pH 7.8, 250 mM imidazole, 200 mM NaCl, 0.5 mM EGTA, 6 mM 2-
mercaptoethanol) with an 88 mL gradient of 20 mM imidazole wash buffer to 250 mM imidazole 
elution buffer. For SaPC and LmPC, the enzymes were eluted in a single step elution with 25–
30 mL elution buffer. 
All purified protein samples were pooled and dialyzed overnight in 1 L of Q-Sepharose buffer 
containing 20 mM triethanolamine (pH 8.0), 50 mM NaCl, 1 mM EGTA, and 2 mM DTT at 4 °C 
in preparation for anion exchange chromatography. Protein was loaded on a 10 mL column of 
Q-Sepharose Fast Flow resin (GE Healthcare) and the column was washed with 60 mL of Q-
Sepharose buffer. The RePC protein was eluted from the resin in Q-Sepharose buffer using a 
linear gradient from 50 mM to 1 M NaCl over 88 mL. For SaPC and LmPC, the enzymes were 
eluted in a single step elution with 25–30 mL of Q-sepharose buffer containing 1 M NaCl. 
Fractions were pooled and dialyzed against a storage buffer consisting of 10 mM Tris (pH 7.8), 
150 mM KCl, 3 mM MgCl2, 5% (v/v) glycerol and 2 mM DTT. An Amicon stirred cell with a 
30,000-molecular weight cutoff filter was used to concentrate protein preparations to a range of 
3–12 mg/mL. Concentrated protein was flash-frozen in liquid nitrogen prior to storage at 
−80 °C. 
Preparation of assay reagents and solutions 
All assay reagents and solutions were prepared separately and maintained at 22 °C for the full 
duration of the experiments. All substrates, effectors and enzyme were freshly dissolved and 
diluted in assay buffer containing 50 mM Bis-Tris (pH 7.7), 150 mM KCl, 3.0 mM MgCl2, 0.5% 
triton X-100, and 1% DMSO. The final concentration of enzyme in the 100 μL enzymatic 
reaction was 10 μg/mL, except for LmPC where the final concentration of enzyme in the 100 μL 
enzymatic reaction was 50 μg/mL. Where noted, oxalate and acetyl coenzyme A (Crystal 
Chem Inc., Elk Grove, IL) were included in the 100 μL enzymatic reaction at a final 
concentration of 5 mM and 0.25 mM, respectively. The substrate solution containing NaHCO3, 
pyruvate and ATP was added to the 100 μL enzymatic reaction at a final concentration of 
25 mM, 2 mM, and 1 mM, respectively. EDTA was prepared in assay buffer and served to 
inactivate the enzyme-catalyzed reaction at a final concentration of 12.7 mM. Fast Violet B Salt 
(FVB; Santa Cruz Biotechnology) was prepared at a stock concentration of 46 mM in DMSO. 
After vortexing the FVB stock solution to dissolve the dye, it was centrifuged at 9300 × g for 
1 min and the clarified supernatant was separated from the salt pellet. The resulting FVB stock 
solution was protected from light exposure until it was introduced into the assay. 
Assay procedures 
For all experiments other than the evaluation of the Library of Pharmacologically Active 
Compounds (LOPAC, Sigma), 30 μL enzyme stock solution was added to each well in 96-well, 
flat bottom, polystyrene microplates (Santa Cruz Biotechnology) followed by the addition of 
10 μL of the effectors (oxalate for inhibition, acetyl CoA for activation, assay buffer for the un-
inhibited or un-activated reaction, and EDTA for measurement of the background signal). To 
initiate the enzyme-catalyzed reaction, 60 μL of a substrate stock solution containing pyruvate, 
HCO3− and ATP in assay buffer was added to each well. After 1 h, the enzyme reaction was 
inactivated by the addition of 10 μL of EDTA, followed by the addition of 10 μL of FVB to a final 
volume of 120 μL. The plates were sealed with microseal ‘B’ adhesive seals (Bio-Rad) and 
incubated for 2 h at 22 °C, prior to measuring absorbance values at 530 nm. All plates and 
reagents were maintained at 22 °C for the duration of the experiments. Reagents were 
dispensed using an automated liquid handling system (MultiFlo FX, Biotek) except for the 
effectors which were manually added using a hand-held, multi-channel micropipette. For the 
LOPAC screens, the procedure was slightly modified to incorporate a pintool (V&P Scientific) 
in combination with an Evo system (Tecan Life Sciences) to transfer the controls (0.4 μL) and 
compounds (0.2 μL) after the addition of enzyme. After the addition of the controls, 70 μL of the 
substrate stock solution was added to the wells to initiate the enzyme reaction. 
Data analysis 
The assay signal quality was statistically evaluated using the Z-factor value as described by 
Equation (1) [35], where σs and σc represent the standard deviations for the sample and control, 
respectively, and μs and μc represent the means for the sample and control, respectively. 
𝑍𝑍 = 1 − (3𝜎𝜎𝑠𝑠+3𝜎𝜎𝑐𝑐)
|𝜇𝜇𝑠𝑠−𝜇𝜇𝑐𝑐|
 (1) 
To determine the agreement of the assay in measuring PC activity, the kcat and KM for pyruvate 
were determined by the following method: (1) An OAA standard curve was established to 
relate absorbance values at 530 nm to the OAA concentration. The standard curve was linear 
between 0 and 400 μM [OAA] (described in the results). (2) To determine the kcat and KM 
values using the FVB assay, the enzyme-catalyzed reaction at varying concentrations of 
pyruvate was inactivated at different time intervals. The absorbance values were then 
converted to [OAA] using the standard curve. Initial velocities ([OAA]/minute) were determined 
for each substrate concentration and plotted against pyruvate concentration. Equations (2), (3) 
were used to determine kcat and KM values, where [E]T represents the total enzyme 
concentration, vi represents initial velocity, Vmax represents the maximum velocity and [S] 
represents the substrate concentration: 
𝑣𝑣i =
Vmax[S]
𝐾𝐾M+[S]
 (2) 
𝑘𝑘cat =
Vmax
[E]T
 (3) 
The validation experiments were designed and evaluated according to the recommendations 
of the “Assay Guidance Manual” from the National Center for Advancing Translational 
Sciences (NCATS), which includes all necessary pre-configured spreadsheets for analysis of 
the inter-plate and inter-day experiments [36]. 
For the LOPAC screen, percent activation and percent inhibition were calculated according to 
the equations (4), (5), where μC, μE and μR represent the means for the control (addition of 
acetyl CoA or oxalate), effector (screened small molecule), and reaction (the unaffected 
reaction), respectively: 
Percentactivation = 100 − ((μC–μE
μC−μR
) × 100) (4) 
Percentinhibition = 100 − ((μE–μC
μR−μC
) × 100) (5) 
To determine the potency of specific effectors, the FVB assay was performed at varying 
effector concentrations. The dose-dependent response curves were evaluated using IC50 and 
EC50 equations, according to equation [6]: 
Y = bottom+top−bottom
1+10(logIC50−x)*hillslope)
 (6) 
Curve fitting was performed using the software programs KaleidaGraph and Graphpad Prism. 
Results 
To accelerate the discovery of novel small molecule effectors of PC, it was necessary to 
establish an assay that can accurately measure PC activity in a high-throughput manner. 
Several diazonium salts have previously been utilized to detect OAA formation [26,27,29,30] but, to 
the best of our knowledge, they have never been applied to assay PC activity. Consequently, 
we sought to develop and validate a novel, fixed-time assay to measure PC activity via the 
formation of a colored adduct between the reaction product, OAA, and the diazonium salt, 
FVB. 
FVB formed a colored adduct with OAA with an absorbance maximum at 530 nm, consistent 
with previously reported studies (Fig. 2A) [26,27]. None of the other assay components (HCO3−, 
pyruvate, ATP) contributed substantially to the absorbance at 530 nm in the presence of FVB, 
resulting in a large signal to noise ratio for OAA under all assay conditions. The absorbance at 
530 nm was linear over a wide range of OAA concentrations between 1 and 400 μM, but 
deviated from linearity at OAA concentrations greater than ∼400 μM (Fig. 2B). This deviation 
from linearity has previously been reported [26]. Because of this deviation, the accuracy of the 
assay is expected to decrease at concentrations of OAA in excess of 400 μM. As such, the 
assay was designed to maintain an upper limit of OD530 ∼1 to maximize the signal window 
while ensuring accuracy. In this range, the assay is both reliable and sensitive in measuring 
OAA formation as a function of PC activity. 
 
Fig. 2. Absorbance spectrum and OAA standard curve in the presence of 4 mM FVB. A) The background 
absorbance (yellow) in the assay was measured by the addition of the substrates (2.0 mM pyruvate, 1.0 mM ATP 
and 25 mM HCO3−) and assay buffer. The absorbance spectra recorded in assay buffer in the presence of 
substrates at varying concentrations of OAA are shown for 0.3 mM (pink), 0.6 mM (red) and 1.2 mM (purple) OAA. 
B) The absorbance (530 nm) of the FVB-OAA adduct responds linearly to OAA concentrations between 1 and 
400 μM (solid line, R2 = 0.99), while the dependence of absorbance on concentration begins to deviate from 
linearity at concentrations greater than 400 μM. This deviation can be approximated by a second standard curve 
between 400 and 800 μM (dashed line, R2 = 0.96). Error bars represent the standard deviation from eight 
independent measurements. (For interpretation of the references to color in this figure legend, the reader is 
referred to the Web version of this article.) 
An assay procedure was developed according to the schematic described in Fig. 3. Assay 
conditions were optimized for a 120 μL total reaction volume in a 96-well format. The assay 
comprises three overall steps: 1) a PC catalyzed reaction, 2) PC inactivation with EDTA, and 
3) incubation with FVB. PC was first added to the wells, followed by the addition of the small 
molecule effector. The addition of the small molecules in this order facilitated the pre-
incubation of the enzyme with effector molecules to account for potential slow-binding 
activators or inhibitors [21]. The enzymatic reaction was initiated by the addition of a large 
volume of substrates, to facilitate rapid and complete mixing in each well. EDTA was used to 
inactivate the reaction by chelating and sequestering the essential Mg2+ ions from the BC 
domain active site, immediately rendering the enzyme inactive [37] (Supplementary Figure S1). 
Previous studies have also demonstrated that EDTA assists in preventing diazonium salt 
precipitation [26]. Following enzyme inactivation, FVB was added and absorbance was 
measured at 530 nm following a 2 h incubation. 
 
Fig. 3. 96-well fixed-time assay procedure. The PC-catalyzed reaction is initiated by the addition of substrates 
(2 mM pyruvate, 1 mM ATP, and 25 mM NaHCO3). After 1 h, the PC-catalyzed reaction is inactivated by the 
addition of 12.7 mM EDTA. FVB is subsequently added to a final concentration of 4 mM for 2 h prior to reading the 
absorbance of the FVB-OAA colored adduct at 530 nm. This procedure can be performed manually or with an 
automated liquid handling system. 
To test the ability of the assay to detect activators and inhibitors of PC, the assay procedure 
was validated by measuring the absorbance of the colored FVB-OAA adduct in the presence 
of acetyl CoA (activator) and oxalate (inhibitor). The activator and inhibitor were used to test 
the reliability and signal window of the assay as a prerequisite for its application in small 
molecule dose-dependent measurements. The background reaction was measured in the 
presence of inactivating EDTA and resulted in similar absorbance values (∼0.2 Abs) as the 
inhibited reaction in the presence of 5 mM oxalate. The activated reaction in the presence of 
0.25 mM acetyl CoA resulted in an increase in absorbance (∼1.0–1.2 Abs) when compared to 
the unaltered reaction without any small molecule effectors added (∼0.5–0.6 Abs). The EC50 
value for acetyl CoA (45 μM) and the IC50 value for oxalate (97 μM) were determined for RePC 
(Fig. 4). These values are consistent with published KA and KD values of 10 μM and 130 μM, 
respectively, thus further confirming the reliability of this method [38,39]. These results strongly 
support that the FVB assay can be simultaneously utilized to screen for both activators and 
inhibitors of PC in a HTS program. 
 
Fig. 4. FVB assay optimization and dose dependent response with known effectors of RePC. A) The primary 
assay method was evaluated in the presence of established effectors of PC activity. The “background” signal was 
determined from the reaction of PC in the presence of 12.7 mM EDTA. The “reaction” signal was determined from 
the reaction of PC in the absence of any effectors. The “activation” signal was determined from the reaction of PC 
in the presence of the activator, acetyl CoA (0.25 mM). The “inhibition” signal was determined from the reaction of 
PC in the presence of the inhibitor, oxalate (5 mM). The differences between the group means were statistically 
significant, as determined by one-way ANOVA (F (3, 28) = 5956, p < 0.0001). B) Titration of acetyl CoA gives an 
EC50 value for acetyl CoA of 45 μM. C) Titration of oxalate gives an IC50 value for oxalate of 97 μM. In all plots, 
error bars represent the standard deviation from eight independent measurements. 
To further assess the reliability of this assay, steady-state kinetic constants were determined 
for Rhizobium etli PC (RePC). RePC has been extensively structurally and kinetically 
characterized in the presence of both oxalate and acetyl-CoA, serving as an ideal model 
system for validation. The KM value for pyruvate (1.5 ± 0.3 mM) and the kcat value (120 ± 20 
min−1) were determined for RePC (Supplementary Figure S2) and are consistent with 
previously reported values [40,41]. 
Assays that are transitioned to HTS need to not only be reliable, accurate and sensitive but 
also robust, reproducible and statistically validated [35]. To assess the quality of the assay to be 
transitioned to a HTS platform, PC was statistically evaluated in the presence of both acetyl 
CoA and oxalate. Z-factors can be utilized to compare, evaluate and validate the suitability of 
an assay for HTS. A Z-factor score of 0.5–1.0 indicates that the assay has a high dynamic 
range and low variation in the signal measurements and is an excellent assay. Z′-factors are 
used to determine the overall quality of the assay without interference from small molecule 
effectors. Alternatively, Z-factors take into account the signal separation and error of the assay 
when used with small molecule activators or inhibitors. In order to determine the robustness 
and quality of the assay, Z-factors and Z′-factors were calculated for RePC, Listeria 
monocytogenes PC (LmPC) and Staphylococcus aureus PC (SaPC) (Table 1). PC enzymes 
from multiple source organisms were selected to determine the suitability of various bacterial 
PC enzymes for HTS. The excellent Z-factors for RePC, LmPC and SaPC demonstrate that 
this assay is amenable to high-throughput screening for both activators and inhibitors of PC 
enzymes from a range of organisms. The results suggest, however, that assay conditions must 
be individually optimized for PC enzymes from different species, as demonstrated by the 
increased enzyme concentration (50 μg/mL) required to obtain high Z-factors in the assay 
catalyzed by LmPC. 
Table 1. Z- Factors Determined for the assay of bacterial PC enzymes. 
PC Origin Enzyme [ ] μg/mL Z′-Factor Z-Factor Activation Z-Factor Inhibition Assay Score 
Rhizobium etli 10 0.86 0.85 0.87 Excellent 
Listeria monocytogenes 50 0.70 0.77 0.70 Excellent 
Staphylococcus aureus 10 0.87 0.87 0.87 Excellent 
In consideration of using this assay in a HTS context, a series of additional optimization and 
validation tests were performed using automatic liquid dispensing protocols. Most small 
molecules from screening libraries are dissolved in DMSO and are added at fixed 
concentrations in the screening assays. Thus, it was necessary to evaluate the tolerance of PC 
for DMSO [36]. PC activity was not affected by the presence of 1% DMSO (Supplementary 
Figure S3). Additionally, all reagents were stable at 22 °C for up to 8 h, and the final measured 
absorbance values were stable between 2 and 5 h of incubation with FVB (Fig. 5). A three-day 
plate uniformity assessment using the interleaved-signal format [36] was performed in the 
presence of the inhibitor, oxalate. This demonstrated that the signal windows, Z-factors and 
spatial uniformity meet all criteria for consistent plate readouts across multiple plates and days 
(Fig. 6A). A two-day validation test was performed for activation in the presence of acetyl CoA, 
demonstrating consistent plate readouts across multiple plates and days (Fig. 6B; 
Supplementary Table S1). 
 
Fig. 5. Reagent and signal stability for the FVB-based assay. In all plots, the background signal (black) represents 
the inactivated PC reaction in the presence of 12.7 mM EDTA. The reaction signal (grey) represents the PC 
reaction in the absence of effectors. The activation signal (green) represents the PC reaction in the presence of 
the activator, acetyl-CoA (0.25 mM). The inactivation signal (blue) represents the PC reaction in the presence of 
the inhibitor, oxalate (5 mM). A) All reagents used in the FVB-based assay are stable under all conditions for up to 
8 h at 22 °C. The first assay was run at time zero with freshly prepared reagents. These same reagents were used 
for all subsequent reactions, yielding consistent measurements for up to 480 min beyond the time of the first 
assay. B) Incubation times between 120 and 300 min yield consistent absorbance measurements, indicating that 
the FVB-OAA color adduct is stable for an extended time period, permitting the measurement of plates at any 
time between 2 and 5 h post-incubation with FVB. In both plots, error bars represent the standard deviation from 
eight independent measurements. (For interpretation of the references to color in this figure legend, the reader is 
referred to the Web version of this article.) 
 
Fig. 6. Plate uniformity validation tests for RePC with oxalate and acetyl-CoA. Both plate uniformity tests reveal 
consistent signals across all plates and across multiple days. Well number 0–96, 97–192 and 193–288 refer to 
Day 1, Day 2 and Day 3, respectively. No edge or drift effects were observed and all statistical measures are 
acceptable. A) 3-day inhibition plate uniformity assessment with 5 mM oxalate for the minimal signal (blue 
diamonds), 90 μM oxalate for the IC50 signal (pink squares) and the uninhibited PC reaction for the maximal signal 
(green triangles). B) 2-day activation plate uniformity assessment with 250 μM acetyl-CoA as the maximal signal 
(green triangles), 50 μM acetyl-CoA for the EC50 signal (pink squares) and the uninhibited PC reaction as the 
minimal signal (blue diamonds). (For interpretation of the references to color in this figure legend, the reader is 
referred to the Web version of this article.) 
The FVB assay was used to screen RePC against a LOPAC library (Library of 
Pharmacologically Active Compounds, Sigma) to validate the responsiveness of the assay to a 
library of well-characterized bioactive compounds. RePC was screened against the LOPAC 
library on three separate occasions and reproducibly identified two inhibitors in all three 
iterations of the screen (Fig. 7). Consistent activation and inhibition signals were obtained for 
individual plate controls across all 16 plates and all plates had excellent Z-factors (Fig. 7A and 
B). The screen identified two compounds that resulted in 70–91% inhibition (Fig. 7D). The two 
hit compounds, cisplatin and pyriplatin, were confirmed by dose-dependent response assays, 
yielding IC50 values of 22 μM and 30 μM, respectively (Fig. 8). While the steep dose-response 
curve for these compounds suggests that they are likely acting as non-specific alkylating 
agents [42,43] or promiscuous aggregators [44], the results from the pilot screen nevertheless 
indicate that the assay can reproducibly and reliably identify an appropriate number of potential 
inhibitor hit compounds. The LOPAC pilot screen did not identify any potential activators for 
RePC, indicating that a larger, more diverse library is required to identify activators (Fig. 7C). 
All optimization and validation results indicate that the assay is reproducible, reliable and 
sufficiently sensitive to detect a range of small molecule effectors of PC within screening 
libraries. 
 
Fig. 7. LOPAC (Library of Pharmacologically Active Compounds) screen results for inhibitors and activators of 
Rhizobum etli PC. A) Absorbance signals for individual plate controls. The maximal signal is determined in the 
presence of 250 μM acetyl-CoA (pink squares), the normal PC reaction is determined in the absence of effectors 
(purple squares) and the inhibited reaction is determined in the presence of 5 mM oxalate (blue squares). Error 
bars represent the standard deviation from eight independent measurements. B) Z-factors fall in a range 
considered to be excellent (0.6–0.8) and are consistent across all 16 plates. C) Percent of activation from Screen 
1 of the LOPAC screen D) Combined inhibition data from three individual LOPAC screens (Screen 1, blue; 
Screen 2, pink; and Screen 3, purple). The dashed line represents a threshold of 3× the standard deviation for the 
combined data, equivalent to 45% inhibition. Two compounds consistently exceeded this threshold across all 
three screens. (For interpretation of the references to color in this figure legend, the reader is referred to the Web 
version of this article.) 
 
Fig. 8. Dose dependent response for the two inhibitors, cisplatin and pyriplatin, identified in the LOPAC screen. A) 
Dose-dependent response for the inhibition of R. etli PC in the presence of cisplatin results in an IC50 value of 
22 μM. B) Dose-dependent response for the inhibition of R. etli PC in the presence of pyriplatin results in an IC50 
value of 30 μM. The chemical structures of the hit compounds and the percent of inhibition measured in each of 
the three independent screens are indicated. In both plots, error bars represent the standard deviation from eight 
independent measurements. 
Discussion 
A novel, fixed time assay for PC has been developed that is reliable, sensitive and robust. The 
assay monitors the production of OAA through the formation of a colored adduct between OAA 
and the commercially available diazonium salt of FVB. This offers a simple assay to detect PC 
activity through monitoring an increase in absorbance at 530 nm. The assay can be utilized as 
an alternative method to coupled-enzyme assays for the detection of PC activity. Additionally, 
the assay can readily be transitioned to a multi-well plate format where the reagent stability, 
accuracy and reproducibility is ideal for use in high-throughput screening of small molecule 
libraries for both activators and inhibitors of PC activity. 
While diazonium salts have previously been used to detect the production of OAA, they have 
not specifically been applied to assay PC activity. Diazonium salts such as Fast Red KL, Fast 
Ponceau L and Fast Violet B have been used to detect OAA production from aspartate 
transaminase [26,28,45,46]. Fast Violet B, in particular, has also been utilized to assess 
phosphoenolpyruvate carboxylase activity and has previously been optimized in a microtiter 
plate assay [27,29]. The choice of Fast Violet B over other diazonium salts in this assay is based 
on several factors. Fast Violet B is stable over a pH range of 7.0–7.5 and tolerates the addition 
of both EDTA and detergent [27,28,45,47]. Conversely, Fast Red KL and Fast Ponceau L were 
most stable over a pH range of 4.2–4.6 [26,28,45,46]. Additionally, Fast Violet B has a broad 
absorption peak between 490 and 540 nm compared to the narrower absorption peaks of Fast 
Red KL and Fast Ponceau L (455–467 nm respectively), enabling greater flexibility in the 
assay parameters [26,28]. The red-shifted absorbance wavelength of FVB also reduces the 
likelihood of interference with small molecule effectors. Lastly, FVB has previously been used 
in a microtiter plate-based assay for phosponenolpyruvate carboxylase, indicating that it is 
amenable to the smaller reaction volumes typical of a high throughput screening assay. 
The FVB-based assay is capable of accurately measuring steady state kinetics in PC, 
consistent with a study by Amador and Salvatore (1971) that compared the activity of 
aspartate aminotransferase measured by FVB and Fast Ponceau L to the rates determined by 
a MDH coupled-enzyme assay. Thus, the FVB fixed-time assay can be employed as an 
alternative to the MDH coupled-enzyme assay for standard kinetic measurements of PC 
activity in instances where assay conditions interfere with the coupling enzyme. For example, 
many α-keto acids serve as inhibitors of PC [38] but MDH has been shown to reduce aromatic 
α-keto acids [48], precluding careful inhibition studies using the standard MDH coupled enzyme 
assay. The FVB-based enzyme assay is free of secondary coupling enzymes that might 
otherwise be subject to cross-reactivity and, as such, represents an important and 
complementary tool for detailed kinetic studies of PC. It must be noted that the reaction times 
employed for measuring initial velocity kinetics (0–60 s; Supplementary Figure S2) are 
substantially different from the reaction time that is employed in the high throughput screening 
applications (1 h; Fig. 4, Fig. 5, Fig. 6). In high throughput screening, a 1 h enzyme-catalyzed 
reaction produces an ideal signal window for screening PC effectors, despite deviating from 
initial velocity conditions. Thus, the enzyme reaction times must be selected to coincide with 
the assay objectives: 1 h for high throughput screening vs. 10–60 s for measuring initial 
velocity kinetics. 
While it has many advantages, the FVB assay also has certain limitations that must be 
carefully considered. FVB, like all diazonium salts, has the potential for cross-reactivity with 
nucleophilic compounds. For example, it has previously been demonstrated that FVB forms a 
colored adduct with α-ketoglutarate [26] and occasionally produced false positives due to 
ketosis in serums [46]. Additionally, FVB reacts with high concentrations (>250 μM) of acetyl 
CoA and CoA, resulting in a decrease in the FVB-OAA adduct (Supplementary Figure S4). 
Thus, small molecule activators may be difficult to identify if their interference with FVB-OAA 
colored adduct formation offsets their enhancement of PC activity. This may be one reason 
why PC activators were not observed in the LOPAC screen. It is also likely, however, that it is 
simply more difficult to find activators of PC, as allosteric ligands are generally more difficult to 
detect by HTS [49]. 
Lastly, consideration should be given to determining the appropriate concentration of 
substrates to be used in the FVB assay, particularly where it is being applied as a HTS primary 
screen. Here, the assay has been performed at 2 mM pyruvate, which is less than the 
saturating concentrations of 5–20 mM pyruvate, depending on the source of the PC enzyme. 
This sub-saturating concentration of pyruvate maximizes the signal to noise ratio of the assay 
for RePC but, notably, has not been optimized for LmPC or SaPC. The substrate 
concentrations in a HTS assay will influence the detection of weak inhibitors [22,50]. It was 
determined by Yang et al. that performing inhibitor screens at substrate concentrations near to 
the KM value is ideal to detect competitive, non-competitive and uncompetitive inhibitors [50]. 
Thus, prior to embarking on a detailed HTS program, it will be important to consider the 
substrate concentrations in relation to the KM values of the substrates, particularly if certain 
types of inhibitors (i.e. competitive vs. non-competitive) are being sought against a PC target 
from a desired organism. 
In conclusion, a novel, fixed-time assay to detect PC activity has been established. This assay 
can be used to screen for small molecule effectors of PC or as an alternative method to 
measure steady state enzyme kinetics. The development and validation of this assay will 
enable future HTS for the discovery of small molecule effectors of PC. The resulting small 
molecules that will be discovered and developed using this assay will have great potential as 
biochemical tools to further investigate the regulation and structure of PC, as well as the 
metabolic role that it plays in infection and disease. 
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